首页> 外文期刊>Integrative cancer therapies >Chinese Herbal Medicine and Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Randomized Controlled Trials.
【24h】

Chinese Herbal Medicine and Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Randomized Controlled Trials.

机译:中草药和化学疗法治疗肝细胞癌:一项随机对照试验的荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Hepatocellular carcinoma (HCC), one of the most common malignancies worldwide, is highly resistant to standard therapy. It is unclear whether chemotherapy, arterial embolization, or arterial chemoembolization improve survival advantage enough to justify their high toxicity. Treatment with Chinese herbal medicine has been explored, combining herbs that stimulate host immune response with those that have cytotoxic activity against HCC cells. The authors sought to evaluate the effectiveness of Chinese herbal medicine combined with chemotherapy. The hypothesis was that Chinese herbal medicine added to chemotherapy for the treatment of HCC would improve survival and tumor response, when compared to treatment with chemotherapy alone. METHODS: The authors searched the databases TCMLARS, PubMed, and EMBASE as well as the bibliographies of studies identified in the systematic search for potentially relevant titles or abstracts of studies in any language. They retained those that (1) treated only HCCpatients, (2) were described as randomized or reported that there was no statistical difference between treatment groups, (3) gave patients either Chinese herbal medicine therapy combined with chemotherapy in the treatment group or chemotherapy alone in the control group, and (4) provided data on the number of enrolled subjects and responders and nonresponders for tumor response and survival. The authors used random effects meta-analysis to combine data. RESULTS: Twenty-six studies representing 2079 patients met the inclusion criteria. Chinese herbal medicine combined with chemotherapy, compared to chemotherapy alone, improved survival at 12 months (relative risk [RR], 1.55; 95% confidence interval [CI], 1.39-1.72;P< .000), 24 months (RR, 2.15; 95% CI, 1.75-2.64;P< .000), and 36 months (RR, 2.76; 95% CI, 1.95-3.91;P< .000). Tumor response increased (RR, 1.39; 95% CI, 1.24-1.56;P< .000). CONCLUSIONS: These findings provide promising evidence that combining Chinese herbal medicine with chemotherapy may benefit patients with HCC. Because of the low quality of these studies, these findings should be confirmed through conducting high-quality, rigorously controlled trials.
机译:背景:肝细胞癌(HCC)是全球最常见的恶性肿瘤之一,对标准疗法高度耐药。目前尚不清楚化学疗法,动脉栓塞术或动脉化学栓塞术能否改善生存优势,足以证明其高毒性。已经探索了中草药的治疗方法,将刺激宿主免疫反应的草药与对HCC细胞具有细胞毒活性的草药相结合。作者试图评估中草药联合化疗的有效性。假设是与单纯化疗相比,化学疗法中加入中草药治疗肝癌将改善生存率和肿瘤反应。方法:作者搜索了TCMLARS,PubMed和EMBASE数据库,以及在系统搜索中找到的以任何语言显示的潜在相关标题或摘要的研究书目。他们保留了那些(1)仅对HCC患者进行治疗,(2)被描述为随机分组或报告治疗组之间无统计学差异的那些患者;(3)对患者进行了中草药联合治疗的联合治疗或单独使用化疗的患者(4)提供了有关肿瘤反应和生存率的受试者,反应者和非反应者的数据。作者使用随机效应荟萃分析来合并数据。结果:代表2079名患者的26项研究符合纳入标准。与单纯化疗相比,中草药联合化疗可提高12个月生存率(相对危险度[RR]为1.55; 95%置信区间[CI]为1.39-1.72; P <.000),为24个月(RR为2.15) ; 95%CI,1.75-2.64; P <.000)和36个月(RR,2.76; 95%CI,1.95-3.91; P <.000)。肿瘤反应增加(RR,1.39; 95%CI,1.24-1.56; P <.000)。结论:这些发现提供了有希望的证据,表明中草药与化学疗法联合可以使肝癌患者受益。由于这些研究的质量较低,因此应通过进行高质量,严格对照的试验来证实这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号